Jaafer Golzar is a Cardiology physician affiliated with Advocate Christ Medical Center. OpenAlex indexes 28 publications with 547 citations (h-index 10); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Assessment of the Utility of the Pantheris Small Vessel (SV) System
Sponsor: Avinger, Inc.
- Lutonix or Inpact for tHE tReatment Of fEmeropopliteal Stenosis - Drug Coated Balloon
Sponsor: Wake Forest University Health Sciences
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
23 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
63.7%Statin15.2%Rosuvastatin Calcium76%Atorvastatin Calcium24%Part D≥63 patientsAngiotensin receptor blocker (ARB)7.9%Losartan-Hydrochlorothiazide43%Losartan Potassium38%Valsartan-Hydrochlorothiazide19%Part D<11 patients+ 14 more classes in this area
Blood & clotting
30.9%P2Y12 inhibitor18.6%Clopidogrel100%Part D≥96 patientsFactor Xa inhibitor9%Xarelto73%Eliquis27%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
4.4%GLP-1 receptor agonist3.6%Ozempic100%Part D≥17 patientsCorticosteroid0.8%Prednisone100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Temsirolimus Adventitial Delivery to Improve ANGiographic Outcomes Below the Knee
Journal of Endovascular Therapy
2022 - JetStream Atherectomy for the Treatment of In-Stent Restenosis of the Femoropopliteal Segment: One-Year Results of the JET-ISR Study
Journal of Endovascular Therapy
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Hareth Raddawi, MD
Advocate Christ Medical Center
Deepa Bhupali, MD
Advocate Christ Medical Center
Shabina Ahmed, MD
Advocate Christ Medical Center
Stephen Sokalski, DO
Advocate Christ Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”